Compare DexCom, Inc. (DXCM) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Icl Group Ltd — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while Icl Group Ltd trades at $5.11 (market cap $6.57B). The key difference: DexCom, Inc. is far larger — about 4.3× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ICL | |
|---|---|---|
Market Cap | $28.06B | $6.57B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $7.03 |
52-Week Low | $54.84 | $4.80 |
Enterprise Value | $27.03B | $9.14B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
ICL trades at $5.045, up 0.7% with bearish technical signals despite recent earnings beats. The company maintains stable cash flow with $1.06B from operations in 2025, though revenue has declined from $10B in 2022 to $7.15B in 2025. Recent $800M senior notes offering strengthens liquidity while analyst consensus remains entirely neutral with 4 hold ratings.
ICL faces margin compression with net income margin falling to 3.52% amid competitive pressures. The stock's 24.29 P/E suggests full valuation relative to earnings growth. Key risks include raw material cost inflation and foreign exchange volatility, though improved 2026 guidance provides modest upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
